Back Hepatitis B

Hepatitis B

Researchers Discover Structure of Hepatitis B Antigen that Interferes with Immune Response

Researchers from the University of Oxford and the U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases have determined the crystal structure of the hepatitis B "e" antigen (HBeAg), which plays a role in immune tolerance and chronic hepatitis B virus (HBV) infection, according to a study published in the January 8, 2013, issue of the journal Structure. These findings may aid the development of new therapies that improve immune response against the virus.

alt

Read more:

Most Hepatitis B Patients Who Respond to Tenofovir Show Improved Liver Health at 5 Years

Treatment with tenofovir (Viread) remains safe and effective over 5 years, and people who achieve sustained viral load suppression experience improvement in liver histology, including regression of fibrosis and cirrhosis, according to study findings described in the December 7, 2012, advance online edition of The Lancet.

alt

Read more:

AASLD 2012: Patients with Cirrhosis Can Respond Well to Boceprevir or Telaprevir with Careful Monitoring

Real-world experience in the French early-access CUPIC study shows that hepatitis C patients with advanced liver damage can achieve good response to interferon-based triple-therapy including boceprevir (Victrelis) or telaprevir (Incivek), although adverse events are common, according to a presentation at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) last month in Boston.alt

Read more:

FDA Committee Says Heplisav Hepatitis B Vaccine Is Effective, but Safety Data Inadequate

A U.S. Food and Drug Administration (FDA) committee last month concurred that Dynavax's investigational hepatitis B virus (HBV) vaccine Heplisav was effective in preventing infection, but a majority thought there was not enough data to show whether the vaccine is safe.

alt

Read more:

FDA: Do Not Mix Hepatitis B Drug Adefovir with Stribild HIV Combo Pill

The U.S. Food and Drug Administration (FDA) last week announced an update to the label information for adefovir dipivoxil (Hepsera), adding the 4-in-1 antiretroviral combination pill Stribild (elvitegravir/cobicistat/tenofovir/emtricitabine) to the list of other products that should not be co-administered with adefovir.alt

Read more:

AASLD 2012: Entecavir Shows Good Efficacy for Black and Hispanic Hepatitis B Patients

The nucleoside analog entecavir (Baraclude) worked as well for previously untreated African-American and Hispanic/Latino hepatitis B patients as it did for the majority white and Asian study populations in prior clinical trials, according to a poster presented at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) last month in Boston.

alt

Read more:

AASLD 2012: Brivanib Fails to Match Sorafenib for Liver Cancer, but Tivatinib Looks Promising

The investigational cancer drug brivanib did not significantly increase overall survival for patients with hepatocellular carcinoma compared with existing standard therapy, researchers reported at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2012) this month in Boston. But another drug, tivatinib, did appear beneficial for a subset of patients. alt

Read more:

AASLD 2012: Adding Pegylated Interferon to Entecavir Improves HBV Treatment Response

Intensifying entecavir (Baraclude) treatment for hepatitis B by adding pegylated interferon lowers HBV viral load and increases the likelihood of hepatitis B "e" antigen (HBeAg) loss, according to a report at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) last month in Boston. A related study found that hepatitis B surface antigen (HBsAg) levels during treatment can be used to predict response to interferon. alt

Read more:

AASLD 2012: When Are HCV Direct-Acting Antivirals Needed, Who Should Be Prioritized?

When resources for hepatitis C treatment with new direct-acting antivirals are limited, findings from the U.S. suggest that previously untreated people with low HCV viral loads may stand a good chance of achieving sustained virological response without adding telaprevir or boceprevir to pegylated interferon and ribavirin, researchers reported at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) this month in Boston. A related study suggests that younger hepatitis C patients with advanced liver disease should be prioritized for treatment with the new drugs. alt

Read more: